Annals of Surgical Oncology

, Volume 20, Issue 9, pp 2964–2967 | Cite as

Is Potassium Iodide Solution Necessary Before Total Thyroidectomy for Graves Disease?

  • Myrick C. ShinallJr.Email author
  • James T. Broome
  • Arielle Baker
  • Carmen C. Solorzano
Endocrine Tumors



Potassium iodide (KI) has traditionally been used to reduce gland vascularity and diminish blood loss in patients undergoing thyroidectomy for Graves disease (GD). Current American Thyroid Association (ATA) guidelines (Recommendation 22) call for its routine administration in GD but avoidance in toxic multinodular goiter (TMNG).


A retrospective review (July 2008–May 2012) of perioperative data was performed on 162 patients undergoing total thyroidectomy without preoperative KI and compared to 102 patients with TMNG. Statistical analysis included Student’s t test, χ 2 test, and multivariate linear regression.


Compared to TMNG patients, GD patients had a lower mean age (42.7 vs. 49.6 years, p < 0.001) and were less likely to be obese (37 vs. 54 %, p = 0.047). No patients were provided KI in preparation. GD patients did not differ significantly from TMNG patients with respect to mean estimated blood loss (55.4 vs. 51.5 mL, p = 0.773) or mean operative time (131.5 vs. 122.6 min, p = 0.084). GD patients had a lower rate of transient hypocalcemia (31 vs. 49 %, p = 0.004), but the two groups did not statistically differ in rates of prolonged hypocalcemia, temporary recurrent laryngeal nerve (RLN) palsy, prolonged RLN paralysis, or hematoma formation.


Although current ATA recommendations for the management of GD call for routine use of KI before thyroidectomy, this large series demonstrates no appreciable detriment to patient outcomes when this goal is not met.


Recurrent Laryngeal Nerve Total Thyroidectomy Estimate Blood Loss Grave Disease Recurrent Laryngeal Nerve Palsy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors declare no conflict of interest.


  1. 1.
    Plummer HS. Results of administering iodine to patients having exophthalmic goiter. JAMA. 1923;80:1955.Google Scholar
  2. 2.
    Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21:593–646.PubMedCrossRefGoogle Scholar
  3. 3.
    Werga-Kjellman P, Zedenius J, Tallstedt L, Traisk F, Lundell G, Wallin G. Surgical treatment of hyperthyroidism: a ten-year experience. Thyroid. 2001;11:187–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Barakate MS, Agarwal G, Reeve TS, Barraclough B, Robinson B, Delbridge LW. Total thyroidectomy is now the preferred option for the surgical management of Graves’ disease. ANZ J Surg. 2002;72:321–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Chiang FY, Wang LF, Huang YF, Lee KW, Kuo WR. Recurrent laryngeal nerve palsy after thyroidectomy with routine identification of the recurrent laryngeal nerve. Surgery. 2005;137:342–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Lal G, Ituarte P, Kebebew E, Siperstein A, Duh QY, Clark OH. Should total thyroidectomy become the preferred procedure for surgical management of Graves’ disease? Thyroid. 2005;15:569–74.PubMedCrossRefGoogle Scholar
  7. 7.
    Ku CF, Lo CY, Chan WF, Kung AW, Lam KS. Total thyroidectomy replaces subtotal thyroidectomy as the preferred surgical treatment for Graves’ disease. ANZ J Surg. 2005;75:528–31.PubMedCrossRefGoogle Scholar
  8. 8.
    Weber KJ, Solorzano CC, Lee JK, Gaffud MJ, Prinz RA. Thyroidectomy remains an effective treatment option for Graves’ disease. Am J Surg. 2006;191:400–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Gaujoux S, Leenhardt L, Tresallet C, et al. Extensive thyroidectomy in Graves’ disease. J Am Coll Surg. 2006;202:868–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Feliciano DV, Lyons JD. Thyroidectomy is optimal treatment for Graves’ disease. J Am Coll Surg. 2011;212:714–20.PubMedCrossRefGoogle Scholar
  11. 11.
    Hallgrimsson P, Nordenstrom E, Almquist M, Bergenfelz AO. Risk factors for medically treated hypocalcemia after surgery for Graves’ disease: a Swedish multicenter study of 1,157 patients. World J Surg. 2012;36:1933–42.PubMedCrossRefGoogle Scholar
  12. 12.
    Zambudio AR, Rodriguez J, Riquelme J, Soria T, Canteras M, Parrilla P. Prospective study of postoperative complications after total thyroidectomy for multinodular goiters by surgeons with experience in endocrine surgery. Ann Surg. 2004;240:18–25.PubMedCrossRefGoogle Scholar
  13. 13.
    Agarwal G, Aggarwal V. Is total thyroidectomy the surgical procedure of choice for benign multinodular goiter? An evidence-based review. World J Surg. 2008;32:1313–24.PubMedCrossRefGoogle Scholar
  14. 14.
    Rienhoff WF. The histological changes brought about in cases of exophthalmic goiter by the administration of iodine. Bull Johns Hopkins Hosp. 1925;37:285–306.Google Scholar
  15. 15.
    Langley RW, Burch HB. Perioperative management of the thyrotoxic patient. Endocrinol Metab Clin N Am. 2003;32:519–34.CrossRefGoogle Scholar
  16. 16.
    Ansaldo GL, Pretolesi F, Varaldo E, et al. Doppler evaluation of intrathyroid arterial resistances during preoperative treatment with Lugol’s iodide solution in patients with diffuse toxic goiter. J Am Coll Surg. 2000;191:607–12.PubMedCrossRefGoogle Scholar
  17. 17.
    Marigold JH, Morgan AK, Earle DJ, Young AE, Croft DN. Lugol’s iodine: its effect on thyroid blood flow in patients with thyrotoxicosis. Br J Surg. 1985;72:45–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Chang DC, Wheeler MH, Woodcock JP, et al. The effect of preoperative Lugol’s iodine on thyroid blood flow in patients with Graves’ hyperthyroidism. Surgery. 1987;102:1055–61.PubMedGoogle Scholar
  19. 19.
    Coyle PJ, Mitchell JE. Thyroidectomy: is Lugol’s iodine necessary? Ann R Coll Surg Engl. 1982;64:334–5.PubMedGoogle Scholar
  20. 20.
    Marmon L, Au FC. The preoperative use of iodine solution in thyrotoxic patients prepared with propranolol. Is it necessary? Am Surg. 1989;55:629–31.PubMedGoogle Scholar
  21. 21.
    Yabuta T, Ito Y, Hirokawa M, et al. Preoperative administration of excess iodide increases thyroid volume of patients with Graves’ disease. Endocr J. 2009;56:371–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Erbil Y, Ozluk Y, Giris M, et al. Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves’ disease. J Clin Endocrinol Metab. 2007;92:2182–9.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Myrick C. ShinallJr.
    • 1
    Email author
  • James T. Broome
    • 2
  • Arielle Baker
    • 2
  • Carmen C. Solorzano
    • 2
  1. 1.Department of SurgeryVanderbilt University Medical CenterNashvilleUSA
  2. 2.Division of Surgical Oncology and Endocrine SurgeryVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations